## Claims

- 1. A polypeptide which comprises the 237th to 531st amino acid sequence in the amino acid sequence represented by SEQ ID NO:2 and is an enzyme which shows a protease activity.
- 2. A polypeptide consisting of the 237th to 531st amino acid sequence in the amino acid sequence represented by SEQ ID NO:2.
- 3. A polypeptide which comprises the 51st to 531st amino acid sequence in the amino acid sequence represented by SEQ ID NO:2 and is a precursor of an enzyme which shows a protease activity.
- 4. A polypeptide which comprises an amino acid sequence in which the 51st to 531st amino acid sequence in the amino acid sequence represented by SEQ ID NO:2 is conjugated to the C-terminus side of

an amino acid sequence consisting of the 1st to 50th amino acid sequence in the amino acid sequence represented by SEQ ID NO:2, or  $\frac{1}{2}$ 

an amino acid sequence comprising the 1st to 50th amino acid sequence in the amino acid sequence represented

by SEQ ID NO:2 in which 1 to 10 amino acids are deleted, substituted and/or inserted,

and is a precursor of an enzyme which shows a protease activity.

5. A polypeptide consisting of an amino acid sequence represented by SEQ ID NO:2, or

a polypeptide consisting of the 51st to 531st amino acid sequence in the amino acid sequence represented by SEQ ID NO:2.

- 6. A polynucleotide encoding a polypeptide according to any one of claims 1 to 5.
- 7. An expression vector comprising a polynucleotide according to claim 6.
- 8. A cell transformed with an expression vector according to claim 7.
- 9. A method for screening an agent for treating gastrointestinal diseases, which comprises

a step of allowing i) a polypeptide according to claim 1 or claim 2 to contact with ii) a substrate cleavable with said polypeptide and iii) a test substance,

a step of analyzing the cleavage of the substrate and

a step of selecting a substance inhibiting the activity for cleaving the substrate.

- 10. A method for producing a pharmaceutical composition for treating gastrointestinal diseases, which comprises
- a screening step using the screening method according to claim 9 and
- a formulation step using a substance obtainable by the screening.